Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Steatosis and hepatitis C].

Gianni Testino1

  • 1Unità Operativa Dipartimentale Epato-Gastroenterologia, Dipartimento Trapianti di Organo, Azienda Ospedaliera Ospedale San Martino e Cliniche Universitarie Convenzionate, Genova.

Recenti Progressi in Medicina
|February 25, 2006
PubMed
Summary

Hepatitis C virus (HCV) infection increases the risk of non-alcoholic fatty liver disease (NAFLD). Co-infection accelerates liver fibrosis, cirrhosis, and hepatocellular carcinoma, reducing treatment efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MetALD-ALD patients: fate changes in relation to the specialist they meet.

Minerva medica·2026
Same author

Healthy lifestyle programs: good intentions or effective action?

Panminerva medica·2026
Same author

Smoking, healthy lifestyle and adolescence.

Minerva medica·2026
Same author

Building healthier communities: effectiveness and cost-sustainability of the ASL3 GENESIS program for chronic diseases prevention.

Aging clinical and experimental research·2026
Same author

The future of alcoholic liver disease management.

Minerva gastroenterology·2026
Same author

Alcohol-related hepatocellular carcinoma: surveillance and primary prevention.

Journal of liver cancer·2026

Area of Science:

  • Hepatology
  • Virology
  • Metabolic Syndrome

Context:

  • Hepatitis C virus (HCV) infection and non-alcoholic fatty liver disease (NAFLD) are prevalent liver conditions.
  • Epidemiological and experimental data suggest a significant interplay between HCV and NAFLD.
  • The co-occurrence of HCV and steatosis is higher than expected for independent diseases.

Purpose:

  • To explore the relationship between hepatitis C and steatosis.
  • To define distinct forms of fat accumulation in HCV infection: 'metabolic fat' and 'viral fat'.
  • To understand the impact of coexistent steatosis on HCV progression and treatment.

Summary:

  • HCV infection predisposes individuals to NAFLD, with co-infection rates exceeding chance.
  • Two forms of steatosis in HCV are identified: 'metabolic fat' linked to metabolic alterations and 'viral fat' due to direct HCV action.
  • Steatosis presence accelerates fibrosis, cirrhosis, and hepatocellular carcinoma risk, while diminishing antiviral therapy response.

Impact:

  • Steatosis significantly worsens outcomes in hepatitis C patients.
  • Combined treatment approaches addressing both viral and metabolic factors are crucial.
  • Antioxidant therapy is highlighted as a key component in managing co-infected patients.

Related Experiment Videos